MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-MH-18-0256587
Dana Pharmaceuticals Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹1.96 Cr
▼ 78% YoY
Net loss · FY 2025
₹48.23 Lakh
Net margin -24.6%
EBITDA · FY 2025
-₹43.07 Lakh
EBITDA margin -21.9%
Authorised capital
₹4.05 Cr
Registered with MCA
Paid-up capital
₹3.81 Cr
Issued & subscribed
Open charges
₹5.05 Cr
Secured borrowings
Company age
30 yrs
Est. 1996
Employees · EPFO
8
Provident fund records
About Dana Pharmaceuticals Private Limited
Data last updated:
Dana Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 07 August 1996 and has been in existence for over 30 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH1996PTC101669. Its GSTIN is 27AAACD2950R1Z9 (Maharashtra).
The company has an authorised share capital of ₹4.05 Cr and a paid-up capital of ₹3.81 Cr. It is led by directors including Suresh Sagarmal Parmar and Abhai Sachidanand Attavar.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 209 Bhaveshwar Complex Vidyavihar (W) Mumbai – 86., Maharashtra, India.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.96 Cr, a decline of 78% compared to the previous year. For the same year it recorded a net loss of ₹48.23 Lakh (net margin -24.6%) and EBITDA of -₹43.07 Lakh (EBITDA margin -21.9%). Revenue has declined at a compounded annual rate (CAGR) of 40% over three years and 17% over five years.
The company has about 8 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹5.05 Cr on record. Court records list 2 cases involving the company, including 1 filed by the company and 1 filed against it.
Dana Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0256587). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website danagroup.com.
Company details
CIN U24239MH1996PTC101669
Registration Number 101669
Incorporation Date 07 August 1996
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-MH-18-0256587
CIN history
Dana Pharmaceuticals has one previous CIN (Corporate Identification Number): U99999MH1996PTC101669. The current CIN is U24239MH1996PTC101669, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239MH1996PTC101669 | Current |
| U99999MH1996PTC101669 | Previous |
Key People
Suresh Sagarmal Parmar Director Abhai Sachidanand Attavar Director Gautam Hathiramani Ramesh Director Recognitions & Rankings of Dana Pharmaceuticals
Contact details
Dana Pharmaceuticals Private Limited's registered office is in Mumbai, Maharashtra. Its website is danagroup.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address209 Bhaveshwar Complex Vidyavihar (W) Mumbai – 86., Maharashtra, India
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Dana Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Dana Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Dana Pharmaceuticals is trade. In detail, this covers retail trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading |
To see the full business activity and turnover split of Dana Pharmaceuticals Private Limited, buy the company report.
Financials of Dana Pharmaceuticals Private Limited
FY 2025 filings availableDana Pharmaceuticals Private Limited reported revenue of ₹1.96 Cr (down 78% YoY) for FY 2025.
Revenue · FY 2025
₹1.96 Cr ▼ 78%
Net loss · FY 2025
₹48.23 Lakh margin -24.6%
EBITDA · FY 2025
-₹43.07 Lakh margin -21.9%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 78%
3 years · compounded
▼ 40%
5 years · compounded
▼ 17%
EBITDA CAGR growth
1 year
▼ 188%
3 years · compounded
▼ 74%
5 years · compounded
▲ 10%
Revenue has declined at a compounded annual rate (CAGR) of 17% over five years, including a 78% fall in the latest year. EBITDA fell 188% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹43.07 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹48.23 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -21.9% | ||||
| Net Profit Margin | -24.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Dana Pharmaceuticals Private Limited, buy the company report.
Board of directors of Dana Pharmaceuticals Private Limited
Dana Pharmaceuticals has 4 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Suresh Sagarmal Parmar Also directs: Dana Overseas Private Limited | Director | 02 Aug 2022 | 4 Years 2 Months | Current |
| Abhai Sachidanand Attavar Also directs: Dana Overseas Private Limited | Director | 02 Aug 2022 | 4 Years 2 Months | Current |
| Gautam Hathiramani Ramesh Also directs: Dana Overseas Private Limited | Director | 07 Aug 1996 | 30 Years 2 Months | Current |
| Jacky Ramesh Hathiramani Also directs: Dana Overseas Private Limited | Director | 07 Aug 1996 | 30 Years 2 Months | Current |
Auditor
Dana Pharmaceuticals Private Limited is audited by SHAH AND MODI CHARTERED ACCOUNTANTS for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SHAH AND MODI CHARTERED ACCOUNTANTS | FY 2023 | 112426W |
Shareholding
The shareholding of Dana Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Dana Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹5.05 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Mar 2010 | 10213566 | Indian Overseas Bank | ₹1 Cr | Open | |
| 28 Mar 2008 | 10097839 | Indian Overseas Bank | ₹1.8 Cr | Open | |
| 28 Mar 2008 | 10097841 | Indian Overseas Bank | ₹50 Lakh | Open | |
| 15 Oct 1997 | 90360925 | Indian Overseas Bank | ₹35 Lakh | Open | |
| 29 Sep 1997 | 90360918 | Indian Overseas Bank | ₹50 Lakh | Open |
To see the full charge records of Dana Pharmaceuticals Private Limited, buy the company report.
Total charge records: 6 View all charges
Legal cases
Dana Pharmaceuticals Private Limited has 2 court cases on record: 1 filed by Dana Pharmaceuticals, 1 filed against it. All cases are disposed.
Total cases
2
Filed by the company
1
Filed against the company
1
Disposed
2
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 2 | 1 | 0 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Tax appeal | Filed against the company by The Commissioner of Income - Tax-10, Mumbai -400 020. | Disposed |
| Bombay High Court | Writ petition | Filed by the company against The Ambernath Municipal Council and Ors. | Disposed |
To see the full case history of Dana Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Dana Pharmaceuticals Private Limited has 14 MSME Form 1 returns on record between 2019 and 2024, listing 154 overdue payments to 20 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 20)
To see the full MSME payment records of Dana Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Dana Pharmaceuticals Private Limited has a workforce of 8 employees on its EPFO records as of Apr 01, 2024, across 1 active EPFO establishment.
Employee count
8
Active EPFO establishments
1
Employee growth
-11.11%
GST
Dana Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACD2950R1Z9 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Dana Pharmaceuticals Private Limited, buy the company report.
Recent activity
Dana Pharmaceuticals Private Limited has 9 board changes on record since 1996: 4 appointments and 5 cessations. The latest: Abhai Sachidanand Attavar ceased to be Additional Director on 22 Sep 2022.
AGM
Dana Pharmaceuticals Private Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Filing
Dana Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Ceased
Abhai Sachidanand Attavar ceased to be Additional Director.
Ceased
Suresh Sagarmal Parmar ceased to be Additional Director.
Ceased
Anil Kishinchand Gidwani ceased to be Director.
Ceased
Veena Anil Gidwani ceased to be Director.
Appointed
Abhai Sachidanand Attavar was appointed as Director.
Appointed
Suresh Sagarmal Parmar was appointed as Director.
Charges
A charge with Indian Overseas Bank of Rs. 1.00 Cr registered on 26 Mar 2010 with Charge ID 10213566 was modified on 21 Dec 2017.
Ceased
Sabita Ramesh Hathiramani ceased to be Director.
Charges
A charge with Indian Overseas Bank amounted to Rs. 1.00 Cr with Charge ID 10213566 was registered on 26 Mar 2010.
Charges
A charge with Indian Overseas Bank of Rs. 0.50 Cr registered on 28 Mar 2008 with Charge ID 10097841 was modified on 02 Apr 2009.
8 earlier events are in the company report.
Frequently asked questions
Dana Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 07 August 1996 (30+ years old) and is registered under CIN U24239MH1996PTC101669.
Dana Pharmaceuticals has 4 current directors:
- Suresh Sagarmal Parmar - Director
- Abhai Sachidanand Attavar - Director
- Gautam Hathiramani Ramesh - Director
- Jacky Ramesh Hathiramani - Director
The latest financial statements of Dana Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Dana Pharmaceuticals is 27AAACD2950R1Z9, registered in Maharashtra.
The CIN (Corporate Identification Number) of Dana Pharmaceuticals is U24239MH1996PTC101669. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dana Pharmaceuticals has 2 court cases on record: 1 filed by the company and 1 filed against it.
Dana Pharmaceuticals was incorporated on 07 August 1996, making it 30+ years old. It is registered with the Registrar of Companies, Mumbai.
Abhai Sachidanand Attavar ceased to be Additional Director on 22 Sep 2022. Suresh Sagarmal Parmar ceased to be Additional Director on 22 Sep 2022. Anil Kishinchand Gidwani ceased to be Director on 03 Aug 2022. Dana Pharmaceuticals has 9 board changes on record in total.
Yes, Dana Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-MH-18-0256587).
Dana Pharmaceuticals has 14 MSME Form 1 returns on record between 2019 and 2024, listing 154 overdue payments to 20 micro and small suppliers. The latest return was filed on 26 Apr 2024.
Dana Pharmaceuticals can be reached through the website danagroup.com. Its registered office is in Mumbai, Maharashtra, India.